The extent of post-discharge complications has been revealed in the first detailed analysis of Australian data for this group of patients.
Further results from the VOYAGER-PAD trial show use of the agent reduces major cardiovascular events.
Self-reported improvement after exercise programs tends to fall short of objective data, researchers say.
New ‘robust’ research failed to replicate earlier findings signalling an increased mortality risk, conference told.
New results from the VOYAGER PAD trial shows a benefit with no increase in bleeds.
Australian doctors have carried out a network meta-analysis to compare four different approaches to therapy.
A secondary trial analysis shows low-dose rivaroxaban and aspirin benefit high-risk patients with lower extremity PAD, authors say.
It might be worth prescribing other forms of exercise, such as resistance training: researchers.